Isotretinoin Orifarm

Isotretinoin, the active ingredient in Isotretinoin Orifarm, is a retinoid presented as an oral formulation for oral use. It treats severe recalcitrant nodular acne in patients who have not responded to other therapies.

GNH USA supplies Isotretinoin Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotretinoin belongs to the retinoid class and is used for severe forms of acne.

Severe recalcitrant nodular acne: markedly reduces existing lesions and prevents the formation of new nodules. Severe acne vulgaris: clears widespread inflammatory lesions when other treatments have failed. Other severe inflammatory acne: improves skin condition in patients with extensive, resistant acne lesions.

Isotretinoin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dry skin and mucous membranes, including cheilitis. - Ocular dryness and irritation. - Elevated triglyceride levels. - Transient headache or muscle aches.

Serious or Rare Side Effects: - Severe depression or suicidal ideation. - Inflammatory bowel disease. - Hepatotoxicity or significant liver enzyme elevation. - Pancreatitis secondary to hypertriglyceridemia. - Vision changes such as night blindness.

Before initiating therapy, clinicians should assess several safety considerations. - Pregnancy: contraindicated due to high teratogenic risk; ensure effective contraception. - Liver function: monitor hepatic enzymes regularly. - Lipid profile: check triglycerides and cholesterol before and during treatment. - Mood changes: observe for signs of depression or suicidal thoughts. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Isotretinoin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Tetracycline antibiotics: increased risk of intracranial hypertension. - Vitamin A supplements or retinoids: additive teratogenicity and toxicity. - Systemic corticosteroids: may exacerbate pseudotumor cerebri risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in efficacy, consider alternative contraception. - Anticoagulants (e.g., warfarin): potential alteration of INR values. - Lipid‑lowering agents (e.g., fibrates): may affect triglyceride levels. - Antidepressants: monitor mood changes closely.